Article Details

Majority of Patients Treated with Lebrikizumab Achieved Skin Clearance in Lilly's Pivotal ...

Retrieved on: 2022-03-26 22:45:04

Tags for this article:

Click the tags to see associated articles and topics

Majority of Patients Treated with Lebrikizumab Achieved Skin Clearance in Lilly's Pivotal .... View article details on hiswai:

Excerpt

... in the ADvocate program, Eli Lilly and Company (NYSE: LLY) announced today at the American Academy of Dermatology (AAD) Annual Meeting.

Article found on: pipelinereview.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up